



FORMERLY 4Dx

T H E F U T U R E O F L U N G H E A L T H



## Changing The Way We See The Respiratory World

4DMedical (formerly known as 4Dx) is a global medical technology company intent on changing outcomes for patients with lung disease by revolutionizing respiratory imaging and ventilation analysis.

Despite the fact that lung disease accounts for one-sixth of all death and disease around the world, current best practice diagnostic tools are antiquated. Their limitations leave both clinicians and patients without a complete picture of lung health.

Our cutting-edge XV Lung Ventilation Analysis Software (XV LVAS) Ventilation Report is an innovative, first of its kind imaging modality that quantitatively measures the regional lung function. It gives clinicians a clearer picture of lung health for pulmonary disorders including, asthma, COPD, cystic fibrosis and cancer.

In development for more than 15 years, clinical studies for XV Technology began in 2014. We continue to collaborate with many of the world's leading research institutions to better understand how it can advance the diagnosis, treatment and outcomes of patients with pulmonary disease.


**Our vision is a world where people with lung disease have access to better, safer and more effective diagnosis and treatment.**



# Scope of Respiratory Lung Disease

## Fighting for breath

More than 73.4 million diagnostic lung procedures are performed every year in the United States alone, including in patients with asthma, COPD, acute lower respiratory tract infections, pulmonary tuberculosis, lung cancer and cystic fibrosis. The burden extends beyond both economics and medicine, creating immense impact on sufferers and their families.




\* World Health Organization Report 2017

**FDA CLEARED**



**XV LVAS** XV LUNG VENTILATION ANALYSIS SOFTWARE



## Product Overview Software

### XV Technology™

The new benchmark in lung imaging, our patented XV Technology gives a 4-dimensional (3D plus time) view of the lung. Making use of existing hospital equipment, XV Technology operates with a higher sensitivity than any non-invasive competing modality without contrast agents.

### XV Lung Ventilation Analysis Software (XV LVAS)

The XV LVAS Ventilation Report delivers information not available via other modalities. It outputs the quantified regional ventilation data from XV LVAS software into an easy to interpret report that includes 4D visualizations. This enables physicians to detect areas of high and low ventilation with pinpoint accuracy in all parts of the lung, in all phases of the breath.

The report also quantifies ventilation heterogeneity, which is a widely recognized indicator of lung health.

#### Earlier detection, means earlier treatment.

If subtle, functional losses can be detected early, before lung structure is irreversibly affected by disease, treatment can be applied earlier - and this can lead to better outcomes for patients.

### Future Product Development

The next generation of XV Technology reports are currently in development. These include Airway Flow and Expiratory quantification additions to the XV LVAS report and new Contrast-Free Pulmonary Angiography (CFPA) and VQ reports.

*Note: This product has not completed the CE certification for use in the EU. CE certification is anticipated to be completed in 2021.*

# Permetium<sup>TM</sup>

XV Technology<sup>TM</sup> Enhanced



## Product Overview Hardware

### Permetium<sup>TM</sup>

The Permetium is the first commercially dedicated preclinical imaging system that can quantify regional changes in pulmonary function.

Driven by XV Technology and powered by the highest output preclinical generator on the market today, Permetium is elevating respiratory research to unprecedented levels.

### AccuVent 200

A highly versatile small animal ventilator, the AccuVent 200 provides respiratory and preclinical researchers with exceptional accuracy and sensitivity.

The AccuVent 200 is capable of measuring air pressure, airflow and ventilation across a range of volume, pressure and respiratory rates. It's also the only high-frequency ventilator on the market.





## Preclinical & Clinical Studies Collaboration

During the last 15 years, our preclinical trials have consistently demonstrated that XV Technology provides an unprecedented level of detail about a subject's lung health by measuring and displaying the ventilation at each phase of the breath with pinpoint accuracy.

With Permetium scanners installed and a growing list of clinical trials in progress at leading institutions, 4DMedical is developing additional use cases for XV Technology in all major lung diseases.

### Making the leap together

It's our mission to deliver respiratory technologies that drive better patient treatment and outcomes. Creating great impact requires great collaboration.

We've appeared in more than 80 scientific publications and have conducted 15 years of preclinical and clinical trials.

Having collaborated with more than 50 partners around the world, we work together with scientists, engineers and clinicians to make incredible leaps in medicine that can save lives.

To find out more about our products, including our FDA cleared XV LVAS, get in touch with your local 4DMedical team today.  
[info@4dmedical.com](mailto:info@4dmedical.com) | [www.4dmedical.com](http://www.4dmedical.com)

**Australia Office**  
 468 St Kilda Rd. Suite 501  
 Melbourne VIC 3004  
 Australia

**United States Office**  
 21600 Oxnard St. Suite 300  
 Woodland Hills, CA 91367  
 USA

